Abstract: Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by 11 skin barrier disruption. Dermacare is a new cosmetic formulation which enhances moisturization,
Introduction

29
Atopic dermatitis (AD) is a multifactorial chronic inflammatory skin disease characterized by a 
36
It is remarkable to highlight, defects in skin barrier structure, as well as impairment in functional 37 integrity and reduced ability for self-renewal, seem to play a role in triggering both an immune 38 response and nonspecific inflammatory reaction [2] .
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Atopic children show equally important immune deregulation, probably due to a change in the 
69
Clinically, AD is characterized by intense itching, dry skin and periodic outbreaks of eczematous histamine, but other inflammatory mediators are involved [9] . Therefore, oral antihistamines often 80 don't work successfully in relieving itching so the motivation for using them is their sedative effect.
81
In several studies based on quality of life which were carried out in school populations in different 
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The prevalence of AD is estimated to be 15-20% in children and 1-3% in adults, and the incidence 88 has increased by 2-3 times over the past decades in industrialized countries [11] . Literature reports 89 that the incidence is similar in both genders, but there are ethnic and geographic differences that 
93
usually appears between 3 and 6 months of age so that 60% of the cases appear in the first year [12] 94 and around 85% are diagnosed before the age of five. The prevalence of AD in the general population 95 is difficult to determine, but it is estimated that in advanced industrialized countries, around 20% of 96 children suffer from the disease [11, 13] . Most children who suffer from atopic dermatitis don't 3 of 9 present symptoms in adulthood, but it is estimated that between 10 and 30% of patients will continue 98 to suffer from it during adult life [14] .
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Pharmacological treatment must be individually determined for each patient, identifying and 
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The primary outcome was to determine the safety of the new cosmetic product, so any adverse 131 events were recorded, and the investigator assessed the severity of skin irritation caused by the 132 product based on erythema, flaking, pruritus and lichenification. The secondary outcome was to 133 determine the efficacy of the product after the treatment period and to assess the persistent effect of
134
Dermacare after period with habitual treatment. Efficacy was evaluated by means of objective and 135 subjective parameters. The new cosmetic formulation was applied to patients twice daily for 28 days.
136
One of the times, the lotion had to be applied after bathing with Dermacare Syndet cleanser. During 137 this period, oral and topical steroids were not allowed. The nineteen patients were assessed during 3 138 visits (day 0, day 14 and day 28). After the first 28 days, Dermacare treatment was suspended and 139 patients returned to their normal hygiene and moisturizing routines until day 56 when they were 140 assessed a fourth time (Visit day 56). 
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The patients with AD who met eligibility criteria, and gave written informed consent were 143 enrolled in this study. The inclusion criteria were children aged 6 months to 3 years with mild-to- 
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(1), moderate (2) and severe (3).
179
The 
Statistical analysis
189
For the analysis of the evolution of quantitative parameters over time, and due to the great variability,
190
that were presented some data collected in the study, not following a Gaussian distribution, the non- 
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The analysis according to desquamation index was carried out only on those patients (Figure 2 ).
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A reduction in desquamation was observed in 69% of patients at 14 days and in 70% of patients at 28 
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The data obtained from the EASI (Eczema Area and Severity Index) used for initial assessment 
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Treatment tolerance was reported as very good from beginning to end of the study. The quality
233
of life questionnaire (PI-QoL) was administered at baseline visit, after 28 days of treatment with
234
Dermacare and the last visit 28 days after returning to normal treatment. PI-QoL score significantly 235 improved after 28 days of treatment with Dermacare, passing from 7.7 + 4.6 to 4.9 + 3.3, representing 236 a significant improvement of 36.4% (p = 0.046) (Fig.2) . After completing the period of normal cosmetic 237 treatment, patient quality of life worsened with respect to the score obtained after therapy with
238
Dermacare. The mean score increased to 5.6 + 3.7, still representing however a significant 
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The subjective parameters analyzed in the study show that both investigators (IGA) and parents 
303
obtained in the objective parameters were supported by the improvement reported by both the 304 investigators and the parents of the patients, and by the improvement in quality of life.
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The fact observed that improvement during the treatment with Dermacare and the worsening 307 when it was discontinued, suggested that maintenance treatment during remission can increases time 
